Setback on road to recovery for Genzyme’s Allston facility
March 28, 2011Manufacturing and Production Genzyme
Genzyme has been forced to discard one lot of its Fabry disease treatment Fabrazyme (agalsidase beta) manufactured at its troubled …
Kantar Health Names Jim Needell Managing Director, UK
March 28, 2011Kantar Health Names Jim Needell Managing Director, UKNEW YORK, March 28, 2011—Kantar Health, a leading healthcare-focused global consultancy and marketing …
Nycomed files short bowel syndrome treatment
March 28, 2011Medical Communications Nycomed, Revestive, gastrointestinal
Specialist pharma company Nycomed has submitted a novel bowel disease treatment for assessment by European regulators. The Marketing Authorisation Application …
New melanoma drug approved by FDA
March 28, 2011Sales and Marketing BMS, melanoma
Yervoy, Bristol Myers Squibb’s new treatment for advanced skin cancer has gained approval in the US. The drug is the …
Digital Pharma: Social media boost for Pfizer anti-counterfeits campaign
March 28, 2011Medical Communications Digital Pharma blog, Pfizer, counterfeits
Pfizer UK is using social media to reinvigorate its Real Danger patient safety campaign. The next phase of the campaign, …
Telaprevir to be added to standard hep C therapy
March 27, 2011Research and Development, Sales and Marketing hepatitis C, telaprevir
Telaprevir – currently being co-developed by Vertex, Johnson & Johnson and Mitsubishi Tanabe – will become part of a standard …
GSK withdraws applications for Avodart
March 25, 2011Research and Development Avodart, Cancer, GSK, bph, prostate cancer
GlaxoSmithKline has withdrawn all regulatory applications for Avodart to prevent prostate cancer after regulators raised doubts about its benefit/risk profile. …
Working Life: Novartis’ Filiberto de Cal
March 25, 2011Business Services, Sales and Marketing Novartis, Working Life, recruitment
Filiberto de Cal is director of global marketing – new products at Novartis Diagnostics. Here he outlines his route into …
Merck drops oral anticoagulant
March 25, 2011Merck, Pradaxa, Xarelto, anticoagulant, atrial fibrilation, vorapaxar
Merck has given the rights to its oral anticoagulant betrixaban back to Portola Pharmaceuticals after a review of its late …
Sanofi signs ophthalmology research collaboration
March 25, 2011Research and Development Fovea, Sanofi-Aventis, Vision Institute, ophthalmology
Sanofi-Aventis has penned a collaboration with one of the main eye disease research centres in Europe. The three-year agreement between …
Cephalon buys Gemin X for $225 million
March 24, 2011Research and Development Cephalon, lung cancer
Cephalon is to acquire oncology specialist Gemin X and gain access to its cancer candidate obatoclax. The US biopharmaceutical firm …
Bertrand Lehuu joins Aquapharm
March 24, 2011Research and Development appointment, research and development
Scottish marine biotechnology company Aquapharm Biodiscovery has appointed Bertrand Lehuu as senior VP – pharma business. Bertrand has almost 30 …
The Real-Time Rep Becomes a Reality – Changing the Rules of Engagement with Customers
March 24, 2011Sales and Marketing
The Real-Time Rep Defined The Real-Time Rep, no longer a fictitious ideal, is a salesperson who is able to:
Budget provides UK science incentives
March 24, 2011Research and Development George Osborne, R&D tax credits, clinical trials
Chancellor George Osborne has unveiled tax incentives, new funding and moves to cut red tape for the life sciences sector …
Digital Pharma: European pharma and social media
March 24, 2011Medical Communications, Sales and Marketing Digital Pharma blog, Facebook, Twitter, social media, youtube
European pharma is increasingly running local social media initiatives as companies expand on their first, centrally-driven, uses of the technology.Details …
FDA delays decision on Novartis’ COPD drug
March 23, 2011Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol
The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …
Eisai marine sponge derived cancer drug approved in Europe
March 23, 2011Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate
Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …
Kantar Health Names Andrew Miniuks Senior Director, Oncology Market Access
March 23, 2011Kantar Health Names Andrew Miniuks Senior Director, Oncology Market AccessNEW YORK, March 22, 2011—Kantar Health, a leading healthcare-focused global consultancy …
GSK to fund schools science programme
March 23, 2011Research and Development, Sales and Marketing GSK, GlaxoSmithKline, King's College, school science
GlaxoSmithKline has followed its pledge to refund the tuition fees of UK graduates it takes on with a less direct …
Publicis buys Indian health advertising agency
March 23, 2011Medical Communications Publicis Groupe, Publicis Life Brands Watermelon, Watermelon Healthcare Communications, healthcare communications agency, publicis
Publicis Groupe is to acquire a majority stake in a leading Indian healthcare advertising agency, Mumbai-based Watermelon Healthcare Communications. Publicis …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
